A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability-Reference-Cited by-同舟云学术

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability

Published:2016-06-28 Issue:8 Volume:56 Page:1280-1289
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Lipton Richard B.¹²,Manack Adams Aubrey³,Buse Dawn C.¹²,Fanning Kristina M.⁴,Reed Michael L.⁴

Affiliation:

1. The Saul R. Korey Department of NeurologyAlbert Einstein College of MedicineBronx NY USA

2. Montefiore Medical CenterBronx NY USA

3. Allergan plcIrvine CA USA

4. Vedanta ResearchChapel Hill NC USA

Funder

Allergan Foundation

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.12878

Reference35 articles.

1. Paper presented at the International Headache Congress (IHC);Buse DC,2013

2. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

3. Migraine life‐time prevalence in mental disorders: Concurrent comparisons with first‐degree relatives and the general population;Baptista T;Invest Clin.,2012

4. Patterns of Medical Diagnosis and Treatment of Migraine and Probable Migraine in a Health Plan

5. Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine;Headache: The Journal of Head and Face Pain;2024-09-09

2. Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change;Journal of Clinical Medicine;2024-09-03

3. Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial;Headache: The Journal of Head and Face Pain;2024-09-02

4. Patterns of migraine medication use in Norway: A nationwide registry-based observational study;Cephalalgia;2024-08

5. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials;Headache: The Journal of Head and Face Pain;2024-06-22